(Q46431027)

22 December 2017

title

Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension (English)

1 reference

22 December 2017

author

Dimitri P Mikhailidis

2

object named as

Dimitri P Mikhailidis

1 reference

ORCID Public Data File 2021

22 December 2017

1 reference

author name string

John A Papadakis

1

1 reference

22 December 2017

George E Vrentzos

3

1 reference

22 December 2017

Antonia Kalikaki

4

1 reference

22 December 2017

Irene Kazakou

5

1 reference

22 December 2017

Emmanuel S Ganotakis

6

1 reference

22 December 2017

publication date

1 April 2005

1 reference

22 December 2017

Clinical and Applied Thrombosis-Hemostasis

published in

1 reference

22 December 2017

volume

11

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

139-146

1 reference

22 December 2017

A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effects of antihypertensive therapy on haemostatic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effect of fluvastatin on plasma fibrinogen levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Stroke: epidemiology, clinical picture, and risk factors--Part I of III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Epidemiology of fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Valsartan improves fibrinolytic balance in atherosclerotic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Clinical and rheological effects of nifedipine in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Celiprolol in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Impact of lipid and ACE inhibitor therapy on cardiovascular disease and metabolic abnormalities in the diabetic and hypertensive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The association between antihypertensive drug therapies and plasma lipid levels in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

10.1177/107602960501100203

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017